Prosetta

OverviewSuggest Edit

Prosetta Biosciences, Inc. is a 12-year old biotechnology company developing novel small-molecule antiviral therapeutics based on over 25 years of basic research on the Cell-Free Protein Synthesizing Systems (CFPSS) by scientists at the University of California, San Francisco and the University of Washington, Seattle. The incorporation of the CFPSS in our drug discovery platform, has lead to the identification of small molecules which disrupt or alter the key protein-protein interactions involved with the assembly of viral capsids (the protein shell that protects the DNA or RNA genome of a virus). Prosetta has successfully produced highly potent compounds which display activity against multiple strains of many viral families including lead series of molecules that are effective antiviral agents against Influenza, HIV and HCV.
TypePrivate
HQSan Francisco, CA, US
Websiteprosetta.com
Employee Ratings3

Latest Updates

Employees (est.) (Nov 2021)29(+4%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Prosetta

Thomas Higgins

Thomas Higgins

Chairman of the Board of Directors
Vishwanath R. Lingappa

Vishwanath R. Lingappa

Chief Executive Officer, Chief Technology Officer, and Member of the Board of Directors
Karl Manheim

Karl Manheim

Member of the Board of Directors
Dale Bredesen

Dale Bredesen

Member of the Board of Directors
Charles M. Parrish

Charles M. Parrish

Member of the Board of Directors
Show more

Prosetta Office Locations

Prosetta has an office in San Francisco
San Francisco, CA, US (HQ)
670 5th St, San Francisco
Show all (1)

Prosetta Financials and Metrics

Summary Metrics

Prosetta total Funding

$2 m

Prosetta latest funding size

$2 m

Time since last funding

15 years ago
Prosetta's latest funding round in May 2007 was reported to be $2 m. In total, Prosetta has raised $2 m
Show all financial metrics

Prosetta Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Prosetta Online and Social Media Presence

Embed Graph

Prosetta Blogs

Host–rabies virus protein–protein interactions as druggable antiviral targets

Click here for the full articleLingappa UF, Wu X, Macieik A, Yu SF, Atuegbu A, Corpuz M, Francis J, Nichols C, Calayag A, Shi H, Ellison JA, Harrell EK, Asundi V, Lingappa JR, Prasad MD, Lipkin WI, Dey D, Hurt CR, Lingappa VR, Hansen WJ, Rupprecht CE. Host-rabies virus protein-protein interactions a…

Biochemical and biophysical characterization of cell-free synthesized Rift Valley fever virus nucleoprotein capsids enables in vitro screening to identify novel antivirals

Click here for the full articleBroce S, Hensley L, Sato T, Lehrer-Graiwer J, Essrich C, Edwards KJ, Pajda J, Davis CJ, Bhadresh R, Hurt CR, Freeman B, Lingappa VR, Kelleher CA, Karpuj MV. Biochemical and biophysical characterization of cell-free synthesized Rift Valley fever virus nucleoprotein caps…

Divergent effects of Porcupine and Wntless on WNT1 trafficking, secretion, and signaling

Click here for the full articleGalli LM, Zebarjadi N, Li L, Lingappa VR, Burrus LW. Divergent effects of Porcupine and Wntless on WNT1 trafficking, secretion, and signaling. Exp Cell Res. 2016 Sep 10;347(1):171-183. doi: 10.1016/j.yexcr.2016.07.028. Epub 2016 Aug 1. PMID: 27492485; PMCID: PMC5032901…

Disruption of cellular proteostasis by H1N1 influenza A virus causes α-synuclein aggregation

Click here for the full articleMarreiros R, Müller-Schiffmann A, Trossbach SV, Prikulis I, Hänsch S, Weidtkamp-Peters S, Moreira AR, Sahu S, Soloviev I, Selvarajah S, Lingappa VR, Korth C. Disruption of cellular proteostasis by H1N1 influenza A virus causes α-synuclein aggregation. Proc Natl Acad Sc…

Addressing Antiretroviral Drug Resistance with Host-Targeting Drugs—First Steps towards Developing a Host-Targeting HIV-1 Assembly Inhibitor

Click here for the full articleLingappa JR, Lingappa VR, Reed JC. Addressing Antiretroviral Drug Resistance with Host-Targeting Drugs-First Steps towards Developing a Host-Targeting HIV-1 Assembly Inhibitor. Viruses. 2021 Mar 10;13(3):451. doi: 10.3390/v13030451. PMID: 33802145; PMCID: PMC8001593.

Viruses as ‘Truffle Hounds’: Molecular Tools for Untangling Brain Cellular Pathology

Click here for the full articleMüller-Schiffmann A, Trossbach SV, Lingappa VR, Korth C. Viruses as 'Truffle Hounds': Molecular Tools for Untangling Brain Cellular Pathology. Trends Neurosci. 2021 May;44(5):352-365. doi: 10.1016/j.tins.2020.11.004. Epub 2020 Dec 11. PMID: 33317827.
Show more

Prosetta Frequently Asked Questions

  • Who are Prosetta key executives?

    Prosetta's key executives are Thomas Higgins, Vishwanath R. Lingappa and Karl Manheim.

  • How many employees does Prosetta have?

    Prosetta has 29 employees.

  • Who are Prosetta competitors?

    Competitors of Prosetta include Manifold Bio, SFA Therapeutics and Secarna.

  • Where is Prosetta headquarters?

    Prosetta headquarters is located at 670 5th St, San Francisco, San Francisco.

  • Where are Prosetta offices?

    Prosetta has an office in San Francisco.

  • How many offices does Prosetta have?

    Prosetta has 1 office.